CANADABIS CAPITAL INC (CANB.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:CANB - CA13530Q1046 - Common Stock
0.025 CAD
0 (0%)
CANB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. CANB has a medium profitability rating, but doesn't score so well on its financial health evaluation. CANB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CANB has reported negative net income.
CANB had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CANB reported negative net income in multiple years.
CANB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CANB's Return On Assets of -5.26% is in line compared to the rest of the industry. CANB outperforms 60.00% of its industry peers.
CANB has a Return On Equity (-16.69%) which is in line with its industry peers.
CANB's Return On Invested Capital of 1.62% is fine compared to the rest of the industry. CANB outperforms 68.57% of its industry peers.
CANB had an Average Return On Invested Capital over the past 3 years of 12.44%. This is above the industry average of 8.45%.
The last Return On Invested Capital (1.62%) for CANB is well below the 3 year average (12.44%), which needs to be investigated, but indicates that CANB had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.26% | ||
| ROE | -16.69% | ||
| ROIC | 1.62% |
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
1.3 Margins
CANB has a better Operating Margin (1.90%) than 65.71% of its industry peers.
In the last couple of years the Operating Margin of CANB has declined.
CANB has a better Gross Margin (45.50%) than 65.71% of its industry peers.
In the last couple of years the Gross Margin of CANB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.9% | ||
| PM (TTM) | N/A | ||
| GM | 45.5% |
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CANB is creating value.
CANB has about the same amout of shares outstanding than it did 1 year ago.
CANB has more shares outstanding than it did 5 years ago.
CANB has a worse debt/assets ratio than last year.
2.2 Solvency
CANB has an Altman-Z score of 0.19. This is a bad value and indicates that CANB is not financially healthy and even has some risk of bankruptcy.
CANB has a Altman-Z score (0.19) which is in line with its industry peers.
CANB has a Debt/Equity ratio of 1.00. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.00, CANB is not doing good in the industry: 74.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.19 |
ROIC/WACC0.26
WACC6.19%
2.3 Liquidity
CANB has a Current Ratio of 1.33. This is a normal value and indicates that CANB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.33, CANB is doing worse than 60.00% of the companies in the same industry.
CANB has a Quick Ratio of 1.33. This is a bad value and indicates that CANB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.27, CANB is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.27 |
3. Growth
3.1 Past
CANB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -720.00%.
The Revenue for CANB has decreased by -12.84% in the past year. This is quite bad
CANB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.72% yearly.
EPS 1Y (TTM)-720%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-35.88%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CANB. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CANB is valued a bit cheaper than 77.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.06 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CANB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:CANB (1/9/2026, 7:00:00 PM)
0.025
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners53.52%
Ins Owner ChangeN/A
Market Cap3.45M
Revenue(TTM)15.08M
Net Income(TTM)-1.29M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.45 | ||
| P/tB | 0.45 | ||
| EV/EBITDA | 8.06 |
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.11
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.26% | ||
| ROE | -16.69% | ||
| ROCE | 2.15% | ||
| ROIC | 1.62% | ||
| ROICexc | 1.73% | ||
| ROICexgc | 1.73% | ||
| OM | 1.9% | ||
| PM (TTM) | N/A | ||
| GM | 45.5% | ||
| FCFM | N/A |
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
ROICexc(3y)15.4%
ROICexc(5y)N/A
ROICexgc(3y)15.4%
ROICexgc(5y)N/A
ROCE(3y)15.95%
ROCE(5y)N/A
ROICexgc growth 3Y-38.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-38.64%
ROICexc growth 5YN/A
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
F-Score1
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.65 | ||
| Cap/Depr | 7.85% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 0.86 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.27 | ||
| Altman-Z | 0.19 |
F-Score1
WACC6.19%
ROIC/WACC0.26
Cap/Depr(3y)67.82%
Cap/Depr(5y)55.13%
Cap/Sales(3y)2.43%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-720%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-35.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.84%
EBIT growth 3Y-19.31%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-161.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.44%
OCF growth 3YN/A
OCF growth 5YN/A
CANADABIS CAPITAL INC / CANB.CA FAQ
Can you provide the ChartMill fundamental rating for CANADABIS CAPITAL INC?
ChartMill assigns a fundamental rating of 2 / 10 to CANB.CA.
What is the valuation status of CANADABIS CAPITAL INC (CANB.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to CANADABIS CAPITAL INC (CANB.CA). This can be considered as Overvalued.
How profitable is CANADABIS CAPITAL INC (CANB.CA) stock?
CANADABIS CAPITAL INC (CANB.CA) has a profitability rating of 4 / 10.
Can you provide the financial health for CANB stock?
The financial health rating of CANADABIS CAPITAL INC (CANB.CA) is 1 / 10.